118101-09-0

Basic information

• Product Name: L 365260
• Synonyms: L 365260;(+)-1-[[(3R)-2,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin]-3-yl]-3-(3-methylphenyl)urea;(+)-N-[[(3R)-2,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin]-3-yl]-N'-(3-methylphenyl)urea;(3R)-1-Methyl-3-[3-(3-methylphenyl)ureido]-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one;1-[[(3R)-2,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin]-3-yl]-3-(3-methylphenyl)urea;MSD-365260
• CAS NO: 118101-09-0
• Molecular Formula: C24H22N4O2
• Molecular Weight: 398.4571
• Mol File: 118101-09-0.mol

Chemical Properties

• Boiling Point: 611.5°C at 760 mmHg
• Flash Point: 323.6°C
• Appearance: /
• Density: 1.23g/cm³
• Vapor Pressure: 6.85E-15mmHg at 25°C
• Refractive Index: 1.648
• Storage Temp.: Store at +4°C
• Solubility: DMSO: >20mg/mL
• CAS DataBase Reference: L 365260(CAS DataBase Reference)
• NIST Chemistry Reference: L 365260(118101-09-0)
• EPA Substance Registry System: L 365260(118101-09-0)

Safety Data

• Hazard Codes: T,N
• Statements: 25-50/53
• Safety Statements: 45-60-61
• RIDADR: UN2811 - class 6.1 - PG 3 - EHS - Toxic solids, organic, n.o.s.,
• Hazardous Substances Data: 118101-09-0(Hazardous Substances Data)

Usage

Uses

L-365,260 is a non-peptide competitive CCK-BR antagonist.

Biological Activity

Selective cholecystokinin receptor 2 (CCK 2 ) antagonist (IC 50 values are 2 and 280 nM at CCK 2 and CCK 1 receptors respectively) that is inactive at a range of other receptors including opiate, muscarinic acetylcholine, α - and β adrenergic, histamine, angiotensin and bradykinin receptors.

InChI:InChI=1/C24H22N4O2/c1-16-9-8-12-18(15-16)25-24(30)27-22-23(29)28(2)20-14-7-6-13-19(20)21(26-22)17-10-4-3-5-11-17/h3-15,22H,1-2H3,(H2,25,27,30)

Upstream product

• 621-29-4 3-tolyl isocyanate 
• 103421-61-0 3-amino-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 
• 103373-62-2 1,3-dihydro-1-methyl-3-oximido-5-phenyl-2H-1,4-benzodiazepin-2-one 
• 157224-66-3 C₁₉H₁₈N₄O₃ 
• 103343-63-1 3(S)-(2(S)-amino-3-phenylpropanoylamino)-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one 
• 103343-66-4 (S)-3-amino-1-methyl-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 103343-65-3 (3R)-3-amino-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 

Relevant articles and documents

Benzodiazepine analogs

Benzodiazepine analogs of the formula: STR1 wherein: R 3 is STR2 --NH(CH 2) 2 -- 3 NHCOR 7, STR3 or --X 11 NR 18 SO 2 (CH 2) q R 7 ; R 7 is O,S,HH, or NR 15 with the proviso that X 7 can be NR 15 only when R 1 is not H.are disclosed which are antagonists

Carbamate oxime reduction: A new route to C3-amino-1,4-benzodiazepines

A mild reduction method of C3-oximido-1,4-benzodiazepines to afford the C3-amino derivatives is described. The key step involves the formation of a carbamate oxime intermediate. The greater reactivity of the C3-(ethylaminocarbonyl)oximido-1,4-benzodiazepi

Development of 1,4-Benzodiazepine Cholecystokinin Type B Antagonists

A series of 3-(arylureido)-5-phenyl-1,4-benzodiazepines, nonpeptidal antagonists of the peptide hormone cholecystokinin (CCK), are described.Derived by reasoned modification of the CCK-A selective 3-carboxamido-1,4-benzodiazepine, MK-329, this paper chronicles the development of potent, orally effective compounds in which selectivity for the CCK-B recebtor subtype was achieved.The principal lead structure that emerged from these studied is L-365,260, a compound which has been submitted for clinical evaluation.Details of the ability to modulate the receptor interactions of these benzodiazepines by appropriate structure modifications are discussed which imply the possibility of further refining the CCK-B receptor affinity and selectivity of this class of compounds.

Benzodiazepine analogs

Benzodiazepine analogs of the formula: STR1 are disclosed which are antagonists of gastrin and cholecystokinin (CCK).